The aHUS Global Advocate Newsletter: 7th Edition
Written by an international team of aHUS patients and caregivers, the newsletter is an objective look at information and topics important…
Global aHUS at the Baltimore Conference
Global Action will be attending the Foundation’s Baltimore aHUS patients conference from the 28th to the 30th April. Here you will…
The ethics of aHUS patient involvement.
Over the past 10 years the movement of involvement of patients in the development of medicines, their regulation and use has…
Iceland and aHUS
Nearly 400,000 people live in Iceland. At normal prevalence levels there should be two aHUS patients. There are at least three…
Nephmadness and aHUS
In March each year the nephrology community, supported by the American Journal of Kidney Disease, engages in an educational initiative called…
Baltimore -aHUS First Since COVID
Zoom has helped with keeping aHUS advocacy going during the restrictions resulting from the COVID pandemic. Starting a zoom meeting always…
Is incidence of aHUS really “2 per million”?
I know it should not matter so much but whenever I see incidence and prevalence figures for aHUS in articles etc,…
aHUS Community Advisory Board News
Two updates on the Global aHUS Community Advisory Board. There is some information about the inaugural set of CAB / PHARMA…
aHUS trial watch 17- NM8074
Another trial of a complement inhibitor for aHUS treatment has been announced , it is for something currently called NM8074. Full…
- 1
- 2
- 3
- 4
- …
- 6
- Go to the next page